Shares of ProQR Therapeutics NV (NASDAQ:PRQR) gapped down prior to trading on Wednesday . The stock had previously closed at $5.90, but opened at $5.94. ProQR Therapeutics NV shares last traded at $6.00, with a volume of 11,663 shares changing hands.

A number of analysts have issued reports on the company. Leerink Swann reaffirmed a “buy” rating on shares of ProQR Therapeutics NV in a report on Thursday, August 18th. Chardan Capital assumed coverage on ProQR Therapeutics NV in a report on Monday, June 20th. They issued a “neutral” rating and a $4.50 target price on the stock. Finally, Zacks Investment Research lowered ProQR Therapeutics NV from a “hold” rating to a “sell” rating in a report on Saturday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $15.94.

The company has a 50 day moving average price of $5.03 and a 200 day moving average price of $4.90. The stock’s market capitalization is $135.64 million.

ProQR Therapeutics NV (NASDAQ:PRQR) last issued its quarterly earnings results on Wednesday, August 17th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by $0.00. Analysts expect that ProQR Therapeutics NV will post ($1.80) earnings per share for the current fiscal year.

An institutional investor recently raised its position in ProQR Therapeutics NV stock. Jennison Associates LLC increased its stake in ProQR Therapeutics NV (NASDAQ:PRQR) by 3.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,001,774 shares of the biopharmaceutical company’s stock after buying an additional 33,019 shares during the period. Jennison Associates LLC owned approximately 4.29% of ProQR Therapeutics NV worth $8,695,000 as of its most recent SEC filing.

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.